Novartis profit tops expectations as pandemic impact ebbs By Reuters
By Michael Shields ZURICH (Reuters) -Swiss drugmaker Novartis beat second-quarter sales and profit expectations on Wednesday, while keeping its 2021 guidance unchanged, as disruption from the coronavirus pandemic waned. "While demand is starting to return to pre-COVID-19 levels in most geographies and therapeutic areas, we still see a slight impact on parts of our business for example in oncology, generics and certain geographies," it said. "We are assuming further easing of COVID-19 restrictions in the second half of the year with a positive impact on business dynamics." Finance chief Harry Kirsch told reporters that the pandemic...
Подробнее